Design Therapeutics, Inc. (DSGN)

NASDAQ: DSGN · IEX Real-Time Price · USD
13.67
-0.33 (-2.36%)
Dec 5, 2022 4:00 PM EST - Market closed
-2.36%
Market Cap 782.74M
Revenue (ttm) n/a
Net Income (ttm) -57.03M
Shares Out 55.78M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 266,575
Open 13.84
Previous Close 14
Day's Range 13.5 - 14.07
52-Week Range 9.61 - 26.3
Beta n/a
Analysts Buy
Price Target 27.13 (+98.5%)
Earnings Date Nov 7, 2022

About DSGN

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromus... [Read more]

Industry Biotechnology
IPO Date Mar 26, 2021
CEO João Siffert
Employees 56
Stock Exchange NASDAQ
Ticker Symbol DSGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for DSGN stock is "Buy." The 12-month stock price forecast is 27.13, which is an increase of 98.46% from the latest price.

Price Target
$27.13
(98.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Res...

Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022

1 month ago - GlobeNewsWire

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, fo...

Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022 Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-21...

1 month ago - GlobeNewsWire

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, tod...

2 months ago - GlobeNewsWire

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022

3 months ago - GlobeNewsWire

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

CARLSBAD, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, toda...

4 months ago - GlobeNewsWire

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, toda...

6 months ago - GlobeNewsWire

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Clinical Execution of Lead GeneTAC™ Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of Friedreich Ataxia

6 months ago - GlobeNewsWire

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Tre...

Topline Data from Phase 1 Trial Expected in the Second Half of 2022

8 months ago - GlobeNewsWire

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Phase 1 Trial of DT-216, a Novel FA GeneTAC™  Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon

8 months ago - GlobeNewsWire

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothe...

Treatment with GeneTAC™ Small Molecules Reduced Nuclear Foci and Restored Normal Splicing In Vitro, Supporting Further Development Treatment with GeneTAC™ Small Molecules Reduced Nuclear Foci and Restor...

8 months ago - GlobeNewsWire

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for F...

Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon

9 months ago - GlobeNewsWire

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João S...

9 months ago - GlobeNewsWire

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that Jae K...

10 months ago - GlobeNewsWire

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target.  The analyst Madhu Kumar has caution about the Company's lead indication of Friedrei...

10 months ago - Benzinga

Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results

Clinical Initiation of Lead GeneTAC TM Program for Friedreich Ataxia On-track for the First Half of 2022

1 year ago - GlobeNewsWire

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 Gen...

Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference

1 year ago - GlobeNewsWire

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022

1 year ago - GlobeNewsWire

Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João S...

1 year ago - GlobeNewsWire

Design Therapeutics Expands Board of Directors with Key Appointments

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appoin...

1 year ago - GlobeNewsWire

Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results

Successful $276 Million IPO Completed to Advance GeneTAC TM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development

1 year ago - GlobeNewsWire

Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchas...

CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecule...

1 year ago - GlobeNewsWire

Design Therapeutics Announces Pricing of Initial Public Offering

CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of ser...

1 year ago - GlobeNewsWire

Design Therapeutics sets IPO terms, to be valued at more than $1 billion

Design Therapeutics Inc. has set terms for its initial public offering, in which the California-based biopharmaceutical company focused on gene targeted chimeras (GeneTAC) expects to raise up to $240 mi...

1 year ago - Market Watch